Mats G. Hansson
Mats G. Hansson
Senior Professor of Biomedical Ethics
Mats Hansson is Senior Professor and the former director of the Centre for Research Ethics & Bioethics and has conducted extensive research in biomedical ethics as principal investigator in several multi-disciplinary research projects dealing with issues ranging from ethical, social and legal aspects of the implementation of genetic diagnosis in clinical practice and the use of human tissue materials in research, to clinical and medical ethics. He holds an undergraduate degree in biology (1974) and a doctoral degree of theology (1991). Mats Hansson is Professor of Biomedical Ethics.
Phone: +46 18 471 61 97
Mats G. Hansson leads work packages on ethical, legal and social issues in several EU projects on biobank and registry research. He is the principal investigator in Mind the Risk and one of the co-ordinators of BBMRI-ERIC's ELSI common service.
- Åsa Grauman: Self-perceived risk for cardiovascular diseases and preferences for risk information
- Sofia Lavén: Cardiovascular risk communication in primary care
- Karin Schölin Bywall: The value of patient preferences in drug development for rheumatoid arthritis
- Ashkan Atry: Is Fair Play Compatible with Doping in Sport?
- Joanna Forsberg: Ethical aspects of biobank research – Individual rights vs. the public good? (PhD 2012)
- Li Jalmsell: At the intersection of curative and palliative treatment in paediatric oncology (PhD 2015)
- Linus Johnsson: Autonomy and trust in biobank research (PhD 2013)
- Amal Matar: Ethical issues in preconception genetic screening (PhD 2019)
- Malin Masterton: Duties to Past Persons: Moral Standing and Posthumous Interests of Old Human Remains (PhD 2012)
- Jennifer Viberg: How should incidental findings in biobank research and genome sequencing studies be handled? (PhD 2018)
Recently in the media
- Study explores patient preferences in second-line RA treatment
- En ny etikprövningslag behövs, Dagens Medicin, Debatt, 9 February 2016
- Öppenheten förstör chansen till patent, Svenska Dagbladet Debatt, 21 June 2015
- Stora nätverk med patientdata ger chans att höja vården, Dagens Medicin, Debatt, 12 June 2014
- Integritet är en balansgång, Dagens Medicin, 8 November 2013
ACCELERATING DIAGNOSIS FOR RARE DISEASE PATIENTS
We aim to significantly shorten the time required for rare disease diagnosis and efficient intervention using genetic newborn screening and AI-based tools.
Medication safety in pregnancy and breastfeeding
The IMI funded ConcePTION project is building a pan-European ecosystem for generating, monitoring, and providing robust information on medication safety in pregnancy and breastfeeding.
Giving patients a voice in drug development
PREFER is a five year public-private research project where academic researchers and the pharmaceutical industry work together to find out when and where patients want, can and should be involved in drug development
Personalized medicine & preferences
The NordForsk funded NORA project will develop new ways to tailor treatment for individual patients and to integrate patients' own tradeoffs in individualized treatment using digital tools.
Technology, ethics and human rights
Genomics, Enhancement, AI & Robotics
The SIENNA project will address ethical issues in three new and emerging areas with major socio-economic impact.
Stem cell treatment of type 1 diabetes
We provide ethical and legal analysis and guidance on development of products for treating type 1 diabetes, using cells derived from human embryonic stem cells.
Patients accept therapy using embryonic stem cells for Parkinson's disease: a discrete choice experiment
Part of BMC Medical Ethics, 2023.
Part of Developing World Bioethics, 2022.
Attitudes and values among the Swedish general public to using human embryonic stem cells for medical treatment
Part of BMC Medical Ethics, 2022.
Patients' views on using human embryonic stem cells to treat Parkinson's disease: an interview study
Part of BMC Medical Ethics, 2022.
The RD-Connect Genome-Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases
Part of Human Mutation, p. 717-733, 2022.
Communicating test results from a general health checkup: the public’s preferences from a discrete choice experiment survey
Part of Patient Related Outcome Measures, p. 649-660, 2021.
Does being exposed to an educational tool influence patient preferences?: The influence of an educational tool on patient preferences assessed by a discrete choice experiment
Part of Patient Education and Counseling, p. 2577-2585, 2021.
Good general health and lack of family history influence the underestimation of cardiovascular risk: A cross sectional study
Part of European Journal of Cardiovascular Nursing, p. 676-683, 2021.
Biobank and registry ethics & law
For many years, researchers at CRB have provided constructive advise on how to deal with ethical and legal aspects of research using human tissue material and personal data. We have collaborated with biomedical scientists and published our findings in peer reviewed journals. As a summary of this research we have compiled a list of publications with abstracts. We have grouped them thematically to help you find the ones you might be interested in reading. Our publications deal with ethical frameworks and policy, regulatory aspects of biobank and registry research, informed consent, ethical review, integrity concerns, trust, genetic testing, indicental findings, commercialization, public and patient perceptions, rare diseases, children & biobanks & genetics, and biobank studies.
Biobanks as resources for health
Hansson & Levin (eds) 2003
The potential benefits of biomedicine and biotechnology are considerable, but this is also an area of science and medicine that is sometimes found controversial. Decisions made by scientists, by health care professionals and by policymakers must be well informed and based on knowledge and sound research. Legal experts concerned with public law and intellectual property rights, philosophers and social pharmacists have been collaborating with geneticists, pathologists and doctors in several research projects in order to seek the kind of biobank management that would satisfy the interests of both the research community and the general public as regards new medicines and forms of treatment, whilst protecting the integrity of the individual. A summary of that research is presented in this book.